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Introduction. Hemothorax is usually related to chest or iatrogenic trauma from procedures such as central lines and thoracentesis.
Spontaneous hemothorax is defined as pleural fluid hematocrit greater than 50% of serum hematocrit in absence of natural or
iatrogenic trauma affecting the lung or pleural space. Coagulopathy secondary to anticoagulant use has been associated with
spontaneous hemothorax.We present a case of spontaneous hemothorax in a patient taking apixaban for venous thromboembolism
disease. To our knowledge, this is the first case report of apixaban as a cause of spontaneous hemothorax. Case Presentation. A
56-year-old woman with end-stage renal disease (ESRD) was diagnosed with upper extremity deep vein thrombosis (DVT) one
month prior to presentation and was started on apixaban presented with dyspnea and left-sided pleuritic chest pain for two weeks.
She was found to have left-sided large pleural effusion which was diagnosed as hemothorax. Other etiologies for spontaneous
hemothorax were excluded and drainage by 12-French pigtail catheter achieved total resolution of hemothorax in three days.
Discussion. Apixaban is a DOAC used to prevent stroke or thromboembolic events in patients with nonvalvular atrial fibrillation
and to prevent recurrent venous thromboembolic disease. Events such as gastrointestinal, intracranial, and soft tissue bleeding have
been well-documented. However, bleeding manifestation as hemothorax is seldom reported. Our patient presented with isolated
left-sided large pleural effusionwhichwas diagnosed as spontaneous hemothorax. 12-Fr pigtail catheter drainagewas effective in the
management of our patient and provided total resolution in three days.Conclusion. Spontaneous hemothorax is a rare complication
of anticoagulant therapy and might not exhibit the usual radiological signs of traumatic hemothorax. Health care providers should
have high index of suspicion for spontaneous hemothorax when evaluating new pleural effusion in patients receiving DOACs
therapy. Drainage by small bore pigtail catheter might be as effective as larger chest tubes.
1. Introduction
Hemothorax is defined as pleural fluid with a hematocrit
> 50% of the blood hematocrit. Most cases of hemothorax
are related to chest trauma or iatrogenic trauma from pro-
cedures such as central lines, thoracentesis, pleural biopsy,
or catheterization [1]. Spontaneous hemothorax is less com-
mon, and the causes include malignancies, anticoagulant
medications, aortic dissection, arteriovenous malformations
[AVMs], endometriosis, pulmonary infarctions, and sponta-
neous pneumothorax [1].
Coagulopathy secondary to anticoagulant use has been
associated with spontaneous hemothorax when adminis-
tered in the setting of thromboembolic disease [2, 3].
Anticoagulants such as warfarin, heparin, and enoxaparin
have been reported to be responsible for spontaneous
hemothorax [1]. However, there are only few case reports
of direct oral anticoagulants (DOACs) causing spontaneous
hemothorax [4–6].We present a case of spontaneous massive
hemothorax in patient taking apixaban for venous throm-
boembolism disease. To our knowledge, this is the first case
report of apixaban as a cause of spontaneous hemothorax.
2. Case Presentation
A56-year-oldwomanwith end-stage renal disease (ESRD) on
hemodialysis (HD)was diagnosed with upper extremity deep
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Figure 1: Large Left-Sided pleural effusion with tracheal deviation
to the contralateral side.Also sternalwires fromprevious open-heart
surgery are noted.
vein thrombosis (DVT) one month prior to presentation and
started on apixaban presented with dyspnea and left-sided
pleuritic chest pain for two weeks that have been progressing
slowly. She denied any other respiratory symptoms such
as hemoptysis and cough and had no history of falls nor
trauma. There was no weight loss, fever, night sweats, or
recent travels. She has history of hypertension, diabetes
mellitus, and prosthetic mitral valve replacement and she
takes lisinopril, carvedilol simvastatin, and aspirin. Physical
examination revealed tachypnea and dullness to percussion
of the posterior left hemithorax along with decrease in tactile
fremitus; she remained hemodynamically stable throughout
her hospital stay. Laboratory tests on admission revealed the
following: prothrombin time (PT) of 11.5 seconds, interna-
tional normalized ratio (INR) of 1.03, activated partial throm-
boplastin time (aPTT) of 30.4 seconds, and hemoglobin of 7.0
g/dL. Chest radiograph (CXR) showed opacification of two-
thirds of the left hemithorax with tracheal deviation to the
contralateral side consistent with pleural effusion (Figure 1).
Bedside ultrasound of left hemithorax revealed hypoechoic
fluidwithout loculations. Even though shewas transfused one
unit of packed red blood cells (PRBC), her Hb dropped to 6.7
g/dL on the second day of admission.
Apixaban was held for 48 hours and bedside ultrasound-
guided thoracentesis was performed on the third day of
admission. One liter of bloody fluid was drained and sent
for testing (Figure 2). Pleural fluid analysis was as follows:
hematocrit (Hct) 22%, red blood cells (RBC) 126,000/mm3,
white blood cells (WBC) 1,400/mm3; bacterial gram-stain,
culture, and acid-fast bacilli smear were negative for bacteria
and tuberculosis, respectively, and cytology negative for
malignant cells. Serum Hct was 25% at the time of the thora-
centesis. The finding of pleural fluid analysis was consistent
with hemothorax (pleural Hct to serum Hct ratio 88%). A
chest computed tomography (CT) with intravenous contrast
was done to rule out active bleeding, vascular malformations,
and other causes of spontaneous hemothorax (Figure 3).
Figure 2: Pleural fluid sample. Of note, the whole amount of the
drained fluid (1 liter) had the same color and consistency and did
not clear by the end of drainage.
Figure 3: Chest CT with IV contrast after drainage of one liter.
No vascular malformations, active bleeding, or other sources of
hemothorax were identified. Left-sided pleural effusion was noted
to have different Hounsfield unit when compared to the aorta and
pulmonary artery.
A 12-Fr pigtail catheter was inserted and another one liter
was drained in the first 2 hours which then slowed down to
300ml in the next 24 hours and afterwards 20-30ml daily for 2
days. CXR after drainage showed near-total resolution of the
pleural effusion (Figure 4). The catheter was then removed
and patient was discharged without complications.
3. Discussion
Spontaneous hemothorax is defined as pleural fluid hema-
tocrit greater than 50% of the peripheral blood hematocrit
and the absence of natural or iatrogenic trauma affecting
the lung or pleural space [7]. Massive hemothorax refers
to a blood loss of 1500 mL [8]. Spontaneous hemothorax
secondary to anticoagulant therapy usually presents in setting
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Figure 4: Near-total resolution of left-sided pleural effusion. Left-
sided Pigtail (12-Fr) catheter and sternal wires are noted as well.
of pulmonary embolism early after starting the therapy and
patients with pulmonary infarction are at higher risk of
this complication [1–3, 9–12]. DOACs such as Rivaroxaban
[4] and Dabigatran [5, 6] have been reported to cause
spontaneous hemothorax in setting on pulmonary embolism
and atrial fibrillation, respectively.
Apixaban is a DOAC used to prevent stroke or throm-
boembolic events in patients with nonvalvular atrial fib-
rillation and to prevent recurrent venous thromboembolic
disease [13, 14]. Apixaban is the only direct oral anti-
coagulant (DOAC) with an FDA-approved indication for
use in hemodialysis (HD) patients [15]. Events such as
gastrointestinal, intracranial, and soft tissue bleeding have
been well-documented. However, bleeding manifestation as
hemothorax is seldom reported [13].
Our patient presented with isolated left-sided large
pleural effusion raising the possibility for malignancy
and Microbacterium tuberculosis infection; spontaneous
hemothorax was lower in our differential diagnosis given
the rarity of this condition even in coagulopathic patients
without history of trauma or recent procedure. The hypoe-
choicity of the pleural fluid and the absence of hematocrit sign
on ultrasound images were not consistent with hemothorax
neither. Diagnostic thoracentesis was done after 48 hours of
holding apixaban to avoid bleeding complications.
Thoracentesis was performed under ultrasound guidance
and revealed bloody fluid which fulfilled diagnostic criteria
of hemothorax (pleural fluid with a hematocrit > 50% of the
blood hematocrit) [1].We do not believe that the hemothorax
was iatrogenic for a few reasons; firstly, fluid color and
consistency remained constant during the thoracentesis and
pigtail drainage and did not clear after removal of significant
amount. Secondly, the patient hemoglobin remained stable
after the thoracentesis and did not drop nor did the patient
becomehemodynamically unstable.Thirdly, theCXR showed
improvement in the effusion rather than worsening and CT
chest with intravenous contrast did not show signs of active
bleeding.
We hypothesized that the patient has been slowly bleed-
ing and she did not develop loculations, hematomas, or
echogenicity on bedside ultrasound and CT chest because
of being anticoagulated with apixaban and, in contrast to
traumatic hemothorax, in patients with slower blood loss
such as malignancy-associated hemothoraces, depletion of
clotting factors is more pronounced; hence the usual radio-
logical signs of hemothorax might not be present [7].
a 12-Fr pigtail catheter drainage was chosen rather
than larger bore chest tube because there were no signs
of loculations or hematoma on chest CT and ultrasound
and for patient comfort. Bauman et al. [16] compared
14-Fr pigtail catheter with chest tube in management of
traumatic hemothorax/hemopneumothorax and discovered
similar outcomes in terms of complications and failure rate
and the initial drainage output from pigtail catheters was
not inferior to that of chest tubes. However, the usage
of pigtail catheter was selective; hence they recommended
further multicenter study to provide support for its usage in
traumatic hemothorax and hemopneumothorax.
4. Conclusions
Spontaneous hemothorax is a rare complication of anticoagu-
lant therapy andmight not exhibit the usual radiological signs
of traumatic hemothorax. Health care providers should have
high index of suspicion for spontaneous hemothorax when
evaluating new pleural effusion in patients receiving DOACs
therapy. Drainage by small bore pigtail catheter might be as
effective as larger chest tubes with the added benefit of patient
comfort.
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